



Patent Application
Attorney Docket No. PCS10895ANIS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29th day of September, 2003.

By _____

Janice Denison
(Signature of person mailing)
Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/040,570
In Re Application of Martyn Frank
Burslem
Filed: November 1, 2001
Group Art Unit: 1632
Examiner: Valarie E. Bertoglio
Docket No.: PCS10895ANIS
Customer No.: 28523

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application
Attorney Docket No.PCS10895ANIS

A prompt and favorable response is earnestly solicited.

Date: Sept. 29th, 2003

Respectfully submitted,


Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821

RECEIVED
a6074040,570
TECH CENTER 1600
11/01/2003

INFORMATION DISCLOSURE CITATION TYPE <small>(Use several sheets if necessary)</small>								ATTY. DOCKET NO. PCS10895ANIS		SERIAL NO. 10/040,570				
								APPLICANT Martyn Frank Burslem		GROUP 1632				
FILING DATE 11/01/2001														
U.S. PATENT DOCUMENTS														
EXAMINER INITIALS	TRADE NAME	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		US	0	0	2	5	9	6	9	02/28/02	Forssmann, et al.	A61K	31/47	
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO
	EP	0	4	6	3	7	5	6	06/07/91	International	C07D	487/04		
	EP	0	5	7	9	4	9	6	07/15/93	International	C07D	401/04		
	EP	0	6	0	7	4	3	9	09/30/92	International	C07D	215/00		
	WO	9	5	1	9	9	7	8	07/27/95	International	C07D	471/14		
	WO	9	9	0	2	1	6	1	01/21/99	International	A61K	31/52		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Kodama, K., et al., Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs, <i>Euro. Journal of Pharm.</i> , Vol. 263: 93-99, 1994												
		Kühn, R., et al., Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways, <i>Urol Res</i> , Vol. 28: 110-115, 2000												
		Lee, S., et al., Discovery of potent cyclic GMP phosphodiesterase inhibitors, 2-pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities, <i>J. Med. Chem.</i> , Vol. 38: 3547-3557, 1995												
		Middendorff, R., et al., Multiple roles of the messenger molecule cGMP in testicular function, <i>Andrologia</i> , Vol. 32(1): 55-59, 2000												
		Truss, M., et al., Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future, <i>BJU International</i> , Vol. 83(2): 36-41, 1999												
EXAMINER					DATE CONSIDERED									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE